InvestorsHub Logo
Followers 0
Posts 1185
Boards Moderated 0
Alias Born 11/20/2017

Re: vator post# 430830

Thursday, 12/30/2021 2:03:46 PM

Thursday, December 30, 2021 2:03:46 PM

Post# of 689011
I noticed that, too, and thought the same thing. So this is their new business model? Suing over patent infringements as a revenue stream? What a pathetic joke. This article seems to be clearly setting the table for the obvious trial failure that is coming.


It’s been reported that release of the Top Line Data (TLD) in a peer reviewed medical journal could be a likely next step.



I mean, what kind of sentence is that? ". . . could be a likely . . ." What? They locked the data on or before Oct. 5, 2020! Could she go any further to cast doubt with all this couching? I think it's looking more and more like they aren't going to release the data at all. But hey, those patent infringements seem like a pretty reliable revenue stream! LOL!

We now have people posting about using "synthetic" comparisons instead of the trial's own control arm. It has gone beyond ridiculous. Some people just don't understand how the scientific method works. They think the company can just change all the rules, change all the endpoints, change all the definitions, and use fake cherry-picked comparisons to make their data look good. Does anyone really believe that's going to fly with the FDA? The fact that we are sitting here in total darkness 15 months after the company claims it locked the data and became unblinded tells you all you need to know about how much success they are having with this strategy. This whole thing is such a joke, and it really is bordering on being criminal.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News